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b2AR Antagonists and b2AR Gene Deletion Both
Promote Skin Wound Repair Processes
Christine E. Pullar1,2, Gabrielle S. Le Provost1, Andrew P. O’Leary1, Sian E. Evans1, Brian S. Baier2
and R. Rivkah Isseroff2
Skin wound healing is a complex process requiring the coordinated, temporal orchestration of numerous cell
types and biological processes to regenerate damaged tissue. Previous work has demonstrated that a functional
b-adrenergic receptor autocrine/paracrine network exists in skin, but the role of b2-adrenergic receptor (b2AR)
in wound healing is unknown. A range of in vitro (single-cell migration, immunoblotting, ELISA, enzyme
immunoassay), ex vivo (rat aortic ring assay), and in vivo (chick chorioallantoic membrane assay, zebrafish,
murine wild-type, and b2AR knockout excisional skin wound models) models were used to demonstrate that
blockade or loss of b2AR gene deletion promoted wound repair, a finding that is, to our knowledge, previously
unreported. Compared with vehicle-only controls, b2AR antagonism increased angiogenesis, dermal fibroblast
function, and re-epithelialization, but had no effect on wound inflammation in vivo. Skin wounds in b2AR
knockout mice contracted and re-epithelialized faster in the first few days of wound repair in vivo. b2AR
antagonism enhanced cell motility through distinct intracellular signalling mechanisms and increased vascular
endothelial growth factor secretion from keratinocytes. b2AR antagonism promoted wound repair processes in
the early stages of wound repair, revealing a possible new avenue for therapeutic intervention.
Journal of Investigative Dermatology (2012) 132, 2076–2084; doi:10.1038/jid.2012.108; published online 12 April 2012
INTRODUCTION
Wound healing is a complex process requiring the coordi-
nated, temporal orchestration of numerous cell types and
processes to initiate repair (Shaw and Martin, 2009). The
epidermis can synthesize and secrete a number of proteins
(Boyce, 1994) including epinephrine (Schallreuter et al.,
1992; Pullar et al., 2006b), a ligand for the b-adrenergic
receptors (bARs): b1-adrenergic receptor (b1AR), b2AR, and
b3AR (Wallukat, 2002). They are G protein–coupled recep-
tors highly expressed on all cell lineages in the skin
(McSwigan et al., 1981; Steinkraus et al., 1992; Izeboud
et al., 1999; Iaccarino et al., 2002; de Coupade et al., 2004);
therefore, an autocrine and paracrine bAR network exists in
the epidermis and dermis, respectively.
Previously, nonselective activation or blockade of the
bARs has revealed a regulatory role for bARs in keratinocyte
migration and re-epithelialization. bAR activation decreased
the rate of human keratinocyte (HK) migration in vitro (Pullar
et al., 2003, 2006a; Pullar and Isseroff, 2005), whereas a bAR
antagonist promoted HK migration, by blocking the autocrine
epinephrine-mediated decrease in migration (Pullar et al.,
2006b). In excised human skin, bAR activation delayed
wound re-epithelialization (Pullar et al., 2006a), whereas
bAR antagonism promoted skin re-epithelialization (Pullar
et al., 2006b) in an ex vivo model of chronic wound re-
epithelialization (Kratz, 1998).
In murine skin wound models, stress-induced increases in
epinephrine delayed wound repair (Sivamani et al., 2009;
Romana-Souza et al., 2010a), whereas, conversely, bAR
antagonism enhanced re-epithelialization in a murine skin
burn model in vivo (Sivamani et al., 2009) and accelerated
skin barrier recovery (Denda et al., 2003). In addition, a
nonselective bAR antagonist improved wound healing in
diabetic (Romana-Souza et al., 2009a) and burn-injured
(Romana-Souza et al., 2008) rats and chronically stressed
mice (Romana-Souza et al., 2010b), while delaying repair
in rat acute skin wounds (Souza et al., 2006; Romana-Souza
et al., 2009c).
Here the effect of b2AR antagonism and loss of the b2AR
on the main processes in wound repair were investigated.
The in vitro, ex vivo, and in vivo models allowed a thorough
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mechanistic investigation of skin wound repair at both the
cellular and the tissue level, using a combination of
pharmacological and genetic approaches.
RESULTS
b2AR antagonism promotes angiogenesis
Angiogenesis is an essential process in acute wound
healing (Tonnesen et al., 2000), and endothelial cell (EC)
migration is a critical process in angiogenesis (Eming
et al., 2007). To determine whether a b2AR antagonist
altered EC migration, single-cell migration (SCM) assays
were performed with primary human dermal microvascular
ECs (HDMECs) in the presence and absence of b2AR
antagonist; however, there was no effect on migration rate
(Figure 1a).
To determine whether b2AR antagonism could alter cell
outgrowth from the cut edge of rat aorta (Smith and Staton,
2006), aortic pieces were embedded into the basement
membrane extract and incubated in the presence or absence
of a b2AR antagonist for 5 days. b2AR antagonism increased
aortic outgrowth by 66% after 5 days (Figure 1b).
To investigate angiogenesis in a more complex, multi-
cellular environment in vivo, the chick chorioallantoic
membrane (CAM) assay, a model of embryonic angiogenesis
(Smith and Staton, 2006), was selected. b2AR antagonist
treatment increased angiogenesis by 48% in the CAM assay,
between days 5 and 9 post fertilization (Figure 1c).
Finally, to determine whether b2AR antagonism could
modulate wound angiogenesis in vivo, two full-thickness 6-
mm wounds were created in the dorsal skin of wild-type
(b2ARþ /þ ) and b2AR knockout (b2AR/) mice (Chruscinski
et al., 1999). The wounds were treated immediately after
wounding and then daily, topically, with hydrogel alone or
hydrogel containing 0.1% b2AR antagonist, and photo-
graphed daily. To evaluate the amount of angiogenesis in
the dermis, 7-mm-thick sections from the wound center,
excised after 5 days, were immunostained with an antibody
to an EC marker (CD31), revealing the degree of angiogenesis
in the mouse wounds (Yoon et al., 2009). b2AR antagonist
treatment increased angiogenesis by 26% (Figure 1d). The
amount of angiogenesis in b2AR/ wounds was equal to that
observed in control b2ARþ /þ wounds (Figure 1d), whereas
b2AR antagonist treatment of b2AR/ wounds had no effect
(results not shown).
Vascular endothelial growth factor (VEGF) is a potent pro-
angiogenic factor in acute wounds (Barrientos et al., 2008),
and bAR activation can increase VEGF expression in human
choroid ECs (Steinle et al., 2008). To determine whether
b2AR antagonism increased VEGF secretion from HDMECs,
HKs, human dermal fibroblasts (HDFs), neutrophils, and
macrophages, ELISAs were performed on control and b2AR
antagonist–treated supernatants. VEGF secretion was not
detected in HDMECs or HDF supernatants. Although VEGF
secretion was detected in the supernatants of neutrophils and
macrophages, b2AR antagonist treatment had no effect
(results not shown). However, bAR antagonist treatment
increased the amount of VEGF secreted from HKs after
24 hours by 23% (Figure 1e).
b2AR antagonism promotes human dermal fibroblast migration
in vitro and function in vivo
Within a few days of wounding, fibroblasts proliferate and
migrate into the wound bed (Shaw and Martin, 2009). A
nonselective bAR agonist increased HDF migration via the
src-dependent transactivation of EGFR (Pullar and Isseroff,
2006). To determine the effect of b2AR antagonism on HDF
migration, SCM was performed in the presence and absence
of a highly selective b2AR antagonist. b2AR antagonism
increased the speed of HDF migration by 27% (Figure 2a). In
addition, DFs were isolated from the skin of b2ARþ /þ and
b2AR/ mice. Although a b2AR antagonist increased the
migration speed of b2ARþ /þ murine DFs (MDFs) by 49%,
the speed of b2AR/MDFs was increased by 46% compared
with b2ARþ /þ MDFs (Figure 2b). The b2AR antagonist had
no additional effect on b2AR/ MDF migration speed, as
expected (Figure 2b). Extracellular signal–regulated kinase
(ERK) has an important role in cell migration (Klemke et al.,
1997). b2AR antagonism increased b2ARþ /þ MDF ERK
phosphorylation by 90% (Figure 2c).
To explore whether b2AR antagonism could modulate
wound DF function, two full-thickness 6-mm wounds were
created in the dorsal skin of b2ARþ /þ and b2AR/ mice and
treated daily. Wound area was calculated daily until excision to
determine the rate of wound contraction (Galiano et al.,
2004a), as described in the Materials and Methods section.
Wound contraction was accelerated 4-fold in b2AR antagonist–-
treated b2ARþ /þ wounds and 5-fold in control b2AR/
wounds, 24hours after wounding (Figure 3a). Wound contrac-
tion was still significantly enhanced by 2-fold in b2AR
antagonist–treated b2ARþ /þ wounds and almost 3-fold in
control b2AR/ wounds, 48hours post wounding. After 3 days,
contraction was increased by 19% in b2AR antagonist–treated
b2ARþ /þ wounds and 40% in control b2AR/ wounds, but
after 4 days, contraction of both b2AR antagonist–treated
b2ARþ /þ wounds and control b2AR/ wounds occurred at
the same rate as control b2ARþ /þ wounds. b2AR antagonist–-
treated b2AR/ wounds demonstrated the same rate of wound
contraction as control b2AR/ wounds (Figure 3a).
Expression of a-smooth muscle actin (SMA) is a reliable
marker of myofibroblast differentiation, and the rate of
wound contraction can directly correlate with SMA expres-
sion (Hinz et al., 2001). Sections (7 mm thick) from the wound
center, excised after 5 days, were immunostained with an
antibody to SMA. Populations of SMA-stained fibroblasts
were observed below the wound epithelial margins, 5 days
post wounding. The area of SMA staining was increased by
60% in b2AR antagonist–treated wounds in b2ARþ /þ mice
and was similar in control b2AR/ and b2ARþ /þ wounds
(Figure 3b).
Myofibroblasts synthesize collagen III early in the wound
repair process, which is later replaced by collagen I in more
mature scars (Hinz, 2007). Sections (7 mm thick) from the
wound center, excised after 5 days, were immunostained
with an antibody to collagen III. b2AR antagonist treatment
increased the area of collagen III–stained neo-dermis by
20% in b2ARþ /þ wounds (Figure 3c), whereas control
b2AR/ and b2ARþ /þ wounds had similar areas of
www.jidonline.org 2077
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collagen III staining (Figure 3c). To examine this further,
sections were stained with picrosirius red to assess total
collagen deposition in the neo-dermis (Junqueira et al.,
1979). b2AR antagonist treatment increased the area of
collagen-stained neo-dermis, within 1mm2 of the wound
edge, by 29% in b2ARþ /þ wounds (Figure 3d), whereas
control b2AR/ and b2ARþ /þ wounds had similar areas of
collagen staining (Figure 3d).
b2AR antagonism has no effect on wound inflammation in vivo
Neutrophils and macrophages are recruited to the wound site
to quell bacterial infections, where they secrete a cocktail of
growth factors and cytokines to activate resident keratino-
cytes and fibroblasts (Martin, 1997).
To determine whether a b2AR antagonist could alter the
guidance of inflammatory cells to a wound, a zebrafish
wound model was used. Indeed, zebrafish are known to have
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Figure 1. b2-Adrenergic receptor (b2AR) antagonism promoted wound angiogenesis. (a) Human dermal microvascular endothelial cells (HDMECs) were plated
in the presence or absence of 10 nM bAR antagonist, and single-cell migration (SCM) was performed for 1 hour; see Materials and Methods (control, n¼ 200;
antagonist, n¼ 82). (b) Rat aortic sections were prepared, incubated in the presence or absence of 10 mM bAR antagonist, and imaged every 24 hours; see
Materials and Methods. Representative images of aortas 5 days post-treatment are shown, bar¼ 1mm. The area of outgrowth was measured using the Volocity
software (control, n¼ 4; antagonist, n¼ 4). (c) Fertilized chicken eggs were prepared and chick chorioallantoic membranes (CAMs) were treated with vehicle
alone or with vehicle containing 100 mM b2AR antagonist, from days 5 to 9, and imaged every 24 hours; see Materials and Methods. Representative day 9 images
are shown, bar¼1mm (control, n¼16; antagonist, n¼ 3). (d) Paraffin-embedded wound sections (7 mm) from control and 0.1% bAR antagonist–treated
wild-type (b2ARþ /þ ) mice and control b2-AR knockout (b2AR/) mice day 5 post wounding were immunostained with an anti-CD31 antibody; see Materials
Methods. Representative images are shown, bar¼ 100mm (n¼ 10–14). (e) Human keratinocytes (HKs) were plated for in the presence or absence of 10 nM
b2AR antagonist and prepared for vascular endothelial growth factor-A (VEGF-A) ELISA; see Materials and Methods. Data are representative of five independent
experiments from two separate cell strains. Values plotted are the means±SEM. *Po0.05; **Po0.01.
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two b2AR genes (Steele et al., 2011), but their role in tissue
regeneration is unknown. Zebrafish larvae are transparent
and zebrafish neutrophils are identifiable 48 hours post
fertilization. Upon transection of the caudal fin, neutrophils
are guided to the wound within minutes, but peak neutrophil
recruitment occurs after approximately 6 hours (Renshaw
et al., 2006). When the wounded zebrafish larvae were
immersed in pond water containing a b2AR antagonist, there
was no effect on neutrophil guidance to the caudal fin wound
(Figure 4a).
To determine whether b2AR antagonist treatment altered
wound inflammation in the mouse excisional skin wound
model, 7-mm-thick sections from the wound center, excised
after 3 days, were immunostained with either an antibody to
a polymorphonuclear cell marker (Ly6G-6C) (Fleming et al.,
1993) or a macrophage marker (F4-80) (Austyn and Gordon,
1981). Topical b2AR antagonist treatment or the absence of
the receptor (b2AR/) had no effect on the number of
polymorphonuclear cells or macrophages recruited to the
wound site either 3 or 5 days post wounding (Figure 4b and c;
day 5 results not shown).
b2AR antagonism promotes keratinocyte migration
in vitro and re-epithelialization in vivo
Keratinocyte migration from the wound edges is a critical
process to restore the barrier function of the epidermis, and
they are a valuable source for growth factors in the wound
(Shaw and Martin, 2009).
A b2AR antagonist increased keratinocyte migration
significantly by 12% (Figure 5a). To confirm that murine
keratinocytes (MKs) respond similarly to a b2AR antagonist,
MKs were isolated from newborn b2ARþ /þ and b2AR/
mice and the effect of a b2AR antagonist on motility was
determined. A b2AR antagonist enhanced MK SCM by 28%
(Figure 5b). b2AR/ MKs migrated 16% faster than
b2ARþ /þ MKs, whereas a b2AR antagonist had no additional
effect on their migration, confirming the absence of the b2AR
(Figure 5b). A b2AR antagonist–mediated 2.5-fold increase
in ERK phosphorylation, known to have a pivotal role in
pro-migratory signaling pathways (Klemke et al., 1997),
underpinned its effect on MK motility (Figure 5c).
Tyrosine hydroxylase, the enzyme controlling the rate-
limiting step for catecholamine biosynthesis (Nagatsu et al.,
1964), was expressed in MKs (Figure 5d), and 100±10 and
75±8pgmg1 protein of epinephrine was measured by
enzyme immunoassay in extracts from MKs. MKs similar to
HKs (Pullar et al., 2006b), therefore, can also synthesize
epinephrine, generating an autocrine and paracrine
adrenergic network in the murine epidermis and dermis,
respectively.
Finally, to determine the effect of a b2AR antagonist on
wound re-epithelialization, 7-mm-thick sections from the
wound center, excised after 3 and 5 days, were stained with
hematoxylin and eosin, and the linear distance covered by
new epithelium was determined. b2AR antagonist treatment
increased b2ARþ /þ wound re-epithelialization by 60 and
56% within 3 and 5 days post wounding, respectively
(Figure 5e). In addition, re-epithelialization of b2AR/
wounds was increased by 64% 5 days post wounding
(Figure 5e).
DISCUSSION
b2AR antagonism enhanced angiogenesis ex vivo and in vivo
and increased VEGF secretion from HKs. b2AR antagonism
increased the migration rate of HDFs in vitro, while increasing
SMA expression, collagen III expression, and contractile
ability in murine wounds in vivo. In addition, b2AR/
wounds contracted faster in the first few days post wounding.
In contrast, b2AR antagonism had no effect on wound
inflammation in vivo. Finally, b2AR antagonism or loss of
b2AR increased keratinocyte migration in vitro and promoted
re-epithelialization in vivo within 5 days of wounding. In
summary, b2AR antagonism promoted wound repair, as
summarized in the Supplementary Appendix S1 online.
In previous studies, a nonselective bAR antagonist,
propranolol, improved healing in hospitalized burn patients,
because of its ability to decrease energy expenditure and
muscle protein catabolism (Mohammadi et al., 2009) and
improved wound repair in rabbit skin wounds (Zhang et al.,
2009), diabetic rats (Romana-Souza et al., 2009b), and burn-
injured rats (Romana-Souza et al., 2008). The studies
presented here use a highly selective b2AR antagonist, ICI
118,551 (Bilski et al., 1983), demonstrating for the first
time that selective blockade of the b2AR promotes wound
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Figure 2. b2-Adrenergic receptor (b2AR) antagonism, or the absence of
b2AR, increased dermal fibroblast (DF) migration. (a) Human dermal
fibroblasts (HDFs) were plated, single-cell migration (SCM) was performed for
1 hour, and the mean migration speed was calculated (HDF control, n¼ 107;
b2AR antagonist, n¼112). (b) Murine dermal fibroblasts (MDFs) were
isolated from b2AR knockout (b2AR/) and wild-type (b2ARþ /þ ) neonates
and SCM performed (MDF: b2ARþ /þ control, n¼77, antagonist, n¼ 73;
MDF: b2AR/ control, n¼ 60). (c) Confluent 35-mm2 dishes of MDFs
were stimulated for 10minutes at 37 1C with media alone (control) or
with media containing 10 nM ICI 118,551, samples were prepared, and
western blotting performed for phosphorylated (P-) and total extracellular
signal–regulated kinase (ERK); see Materials and Methods. The data shown
are representative of three independent experiments. Three blots from
separate experiments were scanned and densitometry performed; see
Materials and Methods. Values plotted are the means±SEM. **Po0.01.
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processes, including angiogenesis, DF function, and re-
epithelialization, thus accelerating healing.
The mechanism underpinning the b2AR antagonist–
mediated increase in angiogenesis could be partly attributed
to the b2AR antagonist–mediated increase in VEGF secretion
from HKs, known to be an important source of VEGF (Rossiter
et al., 2004) and other growth factors in wounds (Werner and
Grose, 2003; Barrientos et al., 2008). Indeed, the addition of
autologous cultured keratinocytes can aid healing of chronic
venous leg ulcers (Liu et al., 2004) and the addition of VEGF
promotes healing in chronic diabetic wounds (Galiano et al.,
2004b; Brem et al., 2009); therefore, the b2AR antagonist–-
mediated increase in HK VEGF secretion could be highly
beneficial for wound repair. In the complex wound environ-
ment, b2AR antagonist treatment could also increase the
secretion of other pro-angiogenic factors such as fibroblast
growth factor 2 or basic fibroblast growth factor or platelet-
derived growth factor (Battegay et al., 1994), from wound
cells, which could contribute to the enhanced angiogenesis
observed in vivo. In contrast, post-ischemic angiogenesis was
impaired in b2AR/ mice (Ciccarelli et al., 2011).
The increase in wound contraction observed in b2AR/
wounds (Figure 3a) occurred in the absence of an increase in
SMA-expressing cells in the wound bed (Figure 3b), in
contrast to the observed increase in both wound contraction
and SMA expression in the b2AR antagonist–treated
b2ARþ /þ wounds. Although the rate of wound contraction is
thought to correlate directly with SMA expression (Hinz et al.,
2001), there are several reports describing that wound
contraction can occur in the absence of SMA-expressing
myofibroblasts. Wounds in vanadate-treated rats (Ehrlich
et al., 1999) and rat wounds treated with a Smad blocker, SB-
505124 (Au and Ehrlich, 2010), contracted normally, but SMA-
expressing cells were not detected in the granulation tissue.
Finally, a personal communication from JJ Tomasek reports that
SMA knockout mice heal normally (Hinz, 2007). It appears that
wound contraction is not correlated with SMA expression in
b2AR/ mouse wounds and only b2AR antagonist treatment
can increase SMA expression (Figure 3b).
In addition, blockade of autocrine, endogenously synthe-
sized epinephrine (Figure 5d), inhibitory to keratinocyte
migration (Pullar et al., 2003, 2006a), likely contributed to
the ability of the b2AR antagonist to promote MK migration
in vitro and re-epithelialization in vivo.
Although b2AR antagonist treatment did not alter acute
wound inflammation or the secretion of VEGF from inflam-
matory cells, b2AR blockade has been demonstrated to
attenuate the hyper-inflammatory response to traumatic injury
in mice (Rough et al., 2009). It is possible, therefore, that b2AR
antagonist treatment could reduce persistent or hyper-inflam-
mation, which will be tested in a chronic wound model.
In conclusion, here we report that b2AR antagonism
promotes wound angiogenesis, DF function, and re-epithe-
lialization, enhancing wound repair, thus revealing a possible
new avenue of therapeutic intervention. To our knowledge,
this is previously unreported.
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MATERIALS AND METHODS
Animals
The b2AR-deficient FVB/N (b2AR/) mice were a kind gift from Dr
Brian Kobilka, Stanford University (Stanford, CA) (Chruscinski et al.,
1999). The congenic controls, FVB/N (b2ARþ /þ ) mice, were
purchased from The Jackson Laboratory (Bar Harbor, ME). The
genotypes of the b2ARþ /þ and b2AR–/– mice were confirmed by
PCR, using published primers (Chruscinski et al., 1999). All animals
used in the study were females between 8 and 12 weeks of age. The
University of California, Davis Institutional Animal Care and Use
Committee (IACUC) approved all animal protocols.
Adult zebrafish were maintained, as described (Westerfield,
1994), in compliance with the Animals (Scientific Procedures;
www.legislation.gov.uk/ukpga/1986/14/contents) Act, 1986. Em-
bryos were harvested and raised in egg water (Westerfield, 1994),
at 28.5 1C, until the required developmental stage. Staging was
performed in accordance with (Kimmel et al., 1995).
Culture of primary cells
Primary MKs were isolated from newborn mouse pups, as described
previously (Isseroff et al., 1983), and cultured in MK growth media
(Epilife and keratinocyte growth supplement), 10 ngml1 murine
EGF, 0.1 nM cholera toxin (Invitrogen, Paisley, UK), and 0.5% anti-
biotic solution (25Uml1 penicillin and 25 mgml1 streptomycin
(Sigma Aldrich, Poole, UK), murine keratinocyte complete growth
medium). To isolate MDFs, the remaining dermal pieces were
minced with sterile scissors and transferred to 100-mm plastic cell
culture dishes from Falcon Labware (BD Biosciences, Oxford, UK).
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Figure 4. b2-Adrenergic receptor (b2AR) antagonism has no effect on wound
inflammation. Zebrafish larvae were wounded, untreated, or treated with
500mM b2AR antagonist and imaged using fluorescein-tyramine signal
amplification; see Materials and Methods. (a) The number of neutrophils
recruited to each wounded tail was recorded. Bar¼ 100mm (n¼ 15–30).
Paraffin-embedded murine wound sections (7 mm), day 3 post wounding,
were immunostained with an antibody that recognizes (b) neutrophils
(Ly6G-6C) or (c) macrophages (F4-80). The positive cells per field were
counted and the data analyzed from 10 images of each wound section;
see Materials and Methods (n¼10–14). Values plotted are means±SEM.
FITC, fluorescein isothiocyanate; PMNs, polymorphonuclear cells; TSA,
tyramide signal amplification.
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Figure 5. b2-Adrenergic receptor (b2AR) antagonism, or the absence of
b2AR, increased keratinocyte migration and re-epithelialization. (a) Human
keratinocytes (HKs) and (b) murine keratinocytes (MKs), isolated from b2-AR
knockout (b2AR/) and wild-type (b2ARþ /þ ) neonates, were plated and
single-cell migration (SCM) performed; see Materials and Methods (HK:
control, n¼ 224, antagonist, n¼ 179; MK: b2ARþ /þ control, n¼ 128, b2AR
antagonist, n¼ 102; b2AR/ control¼ 105). MKs were treated with media
alone (control) or with media containing 10 nM b2AR antagonist, and western
blotting for extracellular signal–regulated kinase (ERK) was performed; see
Materials and Methods. (c) Blots were scanned and densitometry performed
using NIH Image J. (d) MK lysates were prepared and western blotting for
tyrosine hydroxylase (TH) was performed. The data shown are representative
of three independent experiments. Control and b2AR antagonist–treated
b2ARþ /þ wounds and control b2AR/ wounds were excised, fixed, and
stained. The percentage of wound re-epithelialization, at days 3 and 5 post
wounding, was calculated using Image J; see Materials and Methods (n¼ 10)
(e). Values plotted are means±SEM. *Po0.05; **Po0.01. P-ERK,
phosphorylated-ERK.
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Dermal pieces were allowed to attach for 5minutes, before the
addition of 4ml of fibroblast growth medium, which consists of
DMEM (basal medium), 0.5% antibiotic solution (25Uml1
penicillin and 25mgml1 streptomycin; Sigma Aldrich), and 10%
fetal calf serum (Invitrogen). The plates were incubated at 37 1C in a
humidified atmosphere of 5% CO2 for 48 hours before adding an
additional 6ml of fibroblast growth medium per dish.
Primary human neonatal DFs were purchased from Invitrogen
and cultured as described previously (Pullar and Isseroff, 2006).
Primary HDMECs were purchased from Invitrogen. Cells were
grown in EC growth media supplemented with microvascular growth
supplement (PromoCell, Heidelburg, Germany) and antibiotics
(25Uml1 penicillin, 25 mgml1 streptomycin; Invitrogen) at 37 1C
with 5% CO2/95% air in a humidified atmosphere. Cells were grown
on attachment factor containing 0.1% gelatin (Invitrogen), and
experiments were conducted using cell passages between 3 and 7.
Primary neonatal HKs were purchased from Invitrogen and
cultured as described previously (Pullar and Isseroff, 2005). At least
three keratinocytes strains, between passages 3 and 6, were used in all
experiments.
SCM assay
Plastic cell culture dishes (35mm) were coated with collagen I
(60mgml1) (Invitrogen) in phosphate-buffered saline for 1 hour at
37 1C. MDFs, isolated from both b2AR/ and b2ARþ /þ mice, and
HDFs were plated at a density of 25 cells per mm2 in fibroblast
growth medium, whereas MKs, HKs, and HDMECs were plated at a
density of 50 cells per mm2, in their appropriate complete media (see
culture methods), for 2 hours at 37 1C. Cells were incubated with
complete media alone (control) or with media containing 10nM b2AR
antagonist (ICI 118,551; Tocris Biosciences, Bristol, UK) at time 0.
The 35-mm dishes were placed in a heating chamber, designed to
maintain the medium at 37 1C, and images were taken every
10minutes for 1 hour with the Improvision software (Perkin Elmer,
Cambridge, UK), as described previously (Pullar et al., 2006b).
Cell treatments for immunoblotting
MKs or MDFs plated at a density of 1 106, isolated from both
b2AR/ and b2ARþ /þ mice, were incubated with either murine
keratinocyte complete growth medium (MK) or fibroblast growth
medium (MDF) alone (control and lysates for catecholamine synthesis
enzyme detection), or with media containing 10nM B2AR antagonist
(ICI, 118551), for 10minutes. Lysates were prepared and electro-
phoresed, as previously described for phosphorylated and total ERK
(Pullar et al., 2003) and tyrosine hydroxylase (Pullar et al., 2006b).
Enzyme immunoassay for the quantitative determination of
epinephrine in small sample volumes
MKs (1 107), isolated from both b2AR/ and b2ARþ /þ mice, were
extracted in 100ml 0.1 N HCl and sonicated on ice for 10minutes.
Extracts were tested in triplicate in an epinephrine enzyme immu-
noassay (Invitrogen) according to the manufacturer’s instructions.
ELISA
Cells were plated on collagen I (30 mgml1)–coated 6-well plates
and incubated for 24 hours in the appropriate complete media to
reach 70/80% confluence. Cells were washed with Hank’s balanced
salt solution and serum starved for 24 hours in the appropriate basal
media. Cells were then incubated with either basal media alone or
media containing 10 mM b2AR antagonist for 6, 24, or 48 hours. After
each time point, media were collected and stored at80 1C for analysis
with a Duoset VEGF-A ELISA kit (R&D Systems, Abingdon, UK).
Rat aortic ring assay
Animals were killed using an approved schedule 1 method. The
abdominal and aortic arcs were extracted from adult Wistar rats and
placed into sterile phosphate-buffered saline. The fibro-adipose
tissue was then removed, and the aortas were washed in warm,
sterile phosphate-buffered saline three times. Aortas were cut into
uniform, 1-mm sections, placed into 80ml of basement membrane
extract (R&D Systems), and incubated at 37 1C for 30minutes. Aortas
were incubated in EC basal media supplemented with 2%
microvascular growth supplement for 3 days, and then with media
alone or media containing 10 mM b2AR antagonist (ICI 118,551) for a
further 5 days. Aortic endothelial outgrowth was imaged every
24 hours, using a Nikon eclipse microscope and the Improvision
Openlab software. The area of outgrowth was analyzed using the
Improvision Volocity software.
Zebrafish caudal fin wound model
Zebrafish larvae, 72 hours post-fertilization, were immersed in pond
water containing 2% tricaine, and complete transection of the tail
was performed with a sterile scalpel blade. After wounding, the
larvae were incubated in the presence or absence of 500 mM b2AR
antagonist (ICI 118,551) for 6 hours, and washed and stained using a
fluorescein-tyramide signal amplification method (Perkin Elmer)
before fixation in 4% paraformaldehyde. Tails were mounted and
photographed on a Nikon TE-2000E inverted microscope at  20
magnification using a fluor objective. The number of neutrophils
recruited to each wounded tail was recorded.
CAM assay
Fertilized eggs were obtained, 1 day post fertilization, from local
hatcheries and incubated at 37 1C in a humidified environment for
48hours. On day 3, approximately 5ml of albumin was removed from
the obtuse poles of the eggs using a 21G cannula. A square window
(2 2cm2) was opened into the shell and shell membrane using a
Dremel tool (Dremel, Uxbridge, UK). The window was then sealed
with Parafilm and incubated horizontally for 48hours at 37 1C. On day
5, water or 100mM b2AR antagonist (ICI 118,551) in water was
evaporated onto the center of a sterile 13-mm coverslip and then
placed face down onto the CAM. CAMs were photographed through
the coverslip center, every 24hours, until day 9 using a stereomicro-
scope (Prior Scientific, Cambridge, UK). Angiogenesis was analyzed
by counting the total number of branch points per field of view
through the center of the coverslip.
Murine wound model
b2AR/ and b2ARþ /þ mice were anesthetized by intraperitoneal
injection of ketamine (100mgkg1)/xylazine (10mgkg1) (Pfizer,
Sandwich, UK). Back skin was shaved and two circular, full-thickness
6-mm excisional wounds were created 2 cm apart, in the center of
the back, using a sterile 6-mm biopsy punch (SMS, Camberley, UK)
to mark the skin for surgical excision. Wounds were treated topically
with 100ml of hydrogel alone (Duoderm, ConvaTec, Uxbridge, UK)
or containing 0.1% (1mM) selective b2AR antagonist (ICI 118,551)
2082 Journal of Investigative Dermatology (2012), Volume 132
CE Pullar et al.
b2AR Antagonism Promotes Wound Healing
(a concentration previously demonstrated to accelerate mouse
epidermal barrier recovery; Denda et al., 2003) immediately after
wounding and daily thereafter until harvesting (n¼ 5–7 mice per
group, two wounds per mouse). Each mouse was housed separately
after wounding until wound harvest. Wounds were left uncovered and
digitally photographed, daily, to determine wound contraction over
time. Wounds were harvested 3 and 5 days post wounding by
carefully applying an 8-mm punch (SMS) around the original wound
and lightly pressing to form an outline on the skin. Scissors were used
to excise the wound without damaging the delicate wound bed.
For histological analysis, the wounds were fixed in an IHC zinc
fixative (BD Biosciences). The zinc-fixed biopsies were bisected,
to ensure that sections were taken from the center of the wound,
dehydrated through an ethanol–xylene series, and embedded in
paraffin. Cross-sections, 7 mm thick, were stained with the
hematoxylin–eosin technique or with picrosirius red, to visualize
collagen in the neo-dermis (Junqueira et al., 1979), as described
by Dapson et al. (2011). Sections were immunostained with an
antibody against SMA (Dako, Ely, UK), collagen III (Rockland,
Lorne Laboratories, Reading, UK), Ly6G-6C (a neutrophil marker;
BD Pharmingen, Oxford, UK), F4-80 (a macrophage marker;
Serotec, Kidlington, UK), or CD31 (an EC marker; BD Pharmin-
gen), followed by DAB detection (BD Pharmingen) according to
the manufacturer’s protocols.
Specimens that were damaged in the histological process or
otherwise non-interpretable were excluded from the study. Re-
epithelialization was determined by examining all hematoxylin- and
eosin-stained sections by light microscopy, using a Q-imaging Retiga-
EX camera attached to a Nikon T-100 inverted microscope, controlled
by the Improvision software. Image J was used to measure the linear
distance covered by new epithelium and the linear distance between
the original wound edges, to determine the percentage of re-
epithelialization. Wound closure was quantified by measuring the
wound area of each wound from the digital pictures taken every day
with Image J. Each picture was calibrated individually. Images of
picrosirius red–stained sections were captured on an Olympus BX51
upright microscope equipped for dark field. The area of the collagen-
stained neo-dermis was analyzed by measuring the red-stained area
within 1mm2 of each wound edge on the dark-field pictures with the
Image J software. Images of the SMA-stained wounds were captured
on a Nikon SMZ-U upright microscope with the Nikon ACT-1
software. Images of the collagen III–stained wounds were captured on
a Nikon Eclipse inverted microscope with the NIS-Elements software.
NIH Image J was used to determine the area of SMA and collagen III
staining in each wound to calculate the mean area of SMA and collagen
III staining in each group. Images of the CD31- ( 40 magnification),
Ly-6G-6C-, and F4-80-stained ( 60 magnification) wounds were also
captured on the Nikon Eclipse microscope. The number of stained
cells/vessels in each image was counted in a double-blind manner,
and the average cell/vessel number was calculated for each group. For
all image analysis, 10 fields were selected from the dermis below the
wound margins and across the wound bed using a template to ensure
that images were captured from similar areas in each wound.
Statistical analysis
Unless mentioned in a specific method, categorical variables were
compared with a two-tailed Fisher’s exact test or a one-way analysis
of variance, followed by the Dunnett’s test, whereas each continuous
variable test group was compared with the control using the two-
tailed Student’s t-test for unpaired data with unequal variance.
Po0.05 (*) was significant and Po0.01 (**) highly significant.
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